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this design is that the binding site of newly synthesized
ab dimers can be occupied prematurely by polypeptides
in the endoplasmic reticulum (Busch et al., 1996) or in
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Melbourne, Victoria 3050 other compartments that they must cross on their way
to the endosomal site(s) where the antigenic peptidesAustralia
²Department of Pathology are generated. To avoid this problem, class II ab dimers
associate in the endoplasmic reticulum with Ii (Cress-Harvard Medical School
Boston, Massachusetts 02115 well, 1994), a chaperone that inserts its so-called CLIP
region (Chicz et al., 1993) into the peptide binding cleft
of the ab dimer (Figure 1). The abIi complex is then
delivered to the endocytic route, where CLIP is removedAntigen-presenting cells (APC) degrade proteins intra-
from the binding site of the ab dimer, thus reactivatingcellularly to generate peptides, which are then bound
the peptide binding capacity of the class II moleculeby products of the major histocompatibility complex
(Figure 1).(MHC) and exposed on the surface of the APC for recog-
The removal of the CLIP segment occurs in severalnition by T cells. The supply of antigenic peptides and
stages. First, Ii is cleaved to generate first the Iip22 (ortheir association with MHC molecules requires the con-
LIP, MW z22 kDa) intermediate and then the Iip10 (orcerted action of a cohort of accessory molecules that
SLIP, MW z10 kDa) degradation intermediate and finallyincludes chaperones, transporters of peptides, and the
CLIP, still attached to the ab dimer (Chapman, 1998).proteases that degrade the antigens (Heemels and
Then, CLIP is exchanged for antigenic peptides in aPloegh, 1995; Wolf and Ploegh, 1995).
reaction catalyzed by the class II±like molecules H2-
DM/H-2DO (in humans, HLA-DM/HLA-DO) (Liljedahl etProteolysis in MHC Class II±Restricted
al., 1998) (Figure 1). Are the enzymes that degrade Ii theAntigen Presentation
same as those that proteolyze the antigens? The identityAntigens delivered from an extracellular source or its
of these enzymes and the consequences of their inhibi-topological equivalent are endocytosed by APC and de-
tion must be assessed.graded in endosomal compartments. These antigens,
generally, will be presented by MHC class II molecules,
which reach the endocytic pathway through association
Dispensability of Cathepsins B and D
with the invariant chain (Ii). The interactions of the Ii
The initial experiments aimed to identify the proteases
subunit with class II molecules include the binding of a
involved in degradation of Ii and/or antigen processing
segment that occupies the class II binding pocket. To
used broadly specific protease inhibitors and implicated
enable antigen presentation, the Ii subunit must be de-
both cysteine and aspartate proteases. Cathepsin (Cat)
stroyed and the class II binding pocket cleared of Ii
B and Cat D, the most abundant cysteine and aspartate
remnants to prepare it for binding of antigenic peptides.
proteases, respectively, were thus proposed as major
The antigenic proteins themselves must be converted
players in antigen presentation (Watts, 1997). In support
proteolytically to generate the appropriate ligands for
of this scenario, purified Cat B and Cat D could degrade
class II molecules. The importance of lysosomal proteol-
Ii as well as antigens in vitro. Moreover, Cat D was
ysis in class II peptide loading has long been recognized:
present in the intracellular compartments of the APC,
drugs that impair lysosomal acidification, such as chlo-
where abIi complexes are converted into ab-peptide.
roquine, impair proteolysis and thus block class II±
However, these studies were hindered by the relative
restricted antigen presentation. This suggests the possi-
lack of specificity of the inhibitors used and because
bility of using protease inhibitors to selectively modify
the in vitro assay conditions for degradation of Ii and/
the presentation of antigenic peptides if the enzyme(s)
or antigens are likely to differ significantly from those
involved in the generation of different peptides vary.
encountered in vivo.
Does the presentation of distinct epitopes require the
The study of knockout mice deficient in Cat B or Cat
same or different proteases? Are there enzymes dedi-
D excluded an essential or even major role of these two
cated to antigen presentation, or are they involved in
enzymes in MHC class II antigen presentation: degrada-
normal ªhouse keepingº functions?
tion of Ii and loading of the bulk of ab dimers with peptide
Endosomal proteolysis is required not only to gener-
were normal in Cat B2/2 or Cat D2/2 APC, and their
ate antigenic peptides but also to provide peptide-
antigen presentation profiles, assessed with several T
receptive class II molecules. The peptide binding site
cell hybridomas specific for distinct combinations of
of class II ab dimers can accommodate peptides of
class II 1 peptide, showed only minor differences com-
variable sequence and length. The APC can thus present
pared to their wild-type counterparts (Villadangos et al.,
to T cells a large array of antigenic peptides using even
1997; Deussing et al., 1998).
a small set of different class II molecules (Rudensky et
al., 1991; Chicz et al., 1993). A possible drawback of
Enter Cathepsins L and S
The cysteine protease Cat S is expressed mostly in APC,³ To whom correspondence should be addressed (e-mail: ploegh@
hms.harvard.edu). and like MHC products and other components of the
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Figure 1. MHC Class II Trafficking and Maturation in the Endocytic Route
The abIi complexes exit the endoplasmic reticulum (ER), traverse the Golgi, and enter the endocytic compartments directly or after transient
expression at the plasma membrane. The relative amount of abIi complexes that intersect the endocytic route at early endosomal, late
endosomal, or lysosomal stations probably varies among differet types of APC. Conversion of abIi into ab-peptide can occur along the entire
endocytic route. A mechanism independent of cysteine proteases and H-2DM/HLA-DM eliminates Ii in early endosomes (EE), enabling some
ab dimers first to capture high molecular weight polypeptides and then to mature into ab-peptide. Most abIi complexes proceed to later
compartments where Ii is eliminated in a stepwise manner by as yet unknown proteases to generate ab-Iip10. This complex is transformed
into ab-CLIP by the action of Cat S (in B cells and DC)/Cat L (in TEC). CLIP is then substituted by antigenic peptides in a reaction catalyzed
by H-2DM/HLA-DM and H-2DO/HLA-DO. A schematic representation of the abIi/Iip41, ab-Iip10, and ab-CLIP complexes is shown at the
bottom.
antigen processing machinery, it is upregulated by inter- of class II at the plasma membrane of Cat S2/2 APC.
Development of CD41 T cells in Cat S2/2 mice wasferon-g (Chapman et al., 1997). Incubation of APC with
the Cat S inhibitor N-morpholinurea-leucyl-homophenyl- normal.
The antibody responses of Cat S2/2 mice to OVA oralanyl-vinylsulfone-phenyl (LHVS) resulted in accumula-
tion of class II ab dimers associated with the degrada- HEL injected in complete Freund's adjuvant, or to colla-
gen type II, were diminished (Nakagawa et al., 1999; Shition intermediate Iip10 (Figure 1). The ab-Iip10 complex
could then be converted in vitro into ab-CLIP by diges- et al., 1999). Compared to the wild-type controls, Cat
S2/2 mice were more deficient in secreting anti-OVAtion with recombinant Cat S (Riese et al., 1996), support-
ing a key role for Cat S in antigen presentation. This role and anti-HEL IgG2 and IgG3 than IgM or IgG1. This
correlated with a lack of germinal centers in the mutanthas been assessed more directly by analysis of Cat S
knockout mice. animals. Perhaps the APC that participates at the initial
stages of the humoral response (characterized by theIn B cells and dendritic cells (DC) deficient in Cat S,
degradation of Ii was interrupted at the Iip10 stage, secretion of IgM and IgG1)Ðpresumably a DC2 is less
dependent on Cat S than are B cells, which must presentresulting in accumulation of ab-Iip10 complexes (Naka-
gawa et al., 1999; Shi et al., 1999). Some of these com- antigenic peptides to T helper cells to induce the forma-
tion of the germinal centers and therefore the secretionplexes were slowly converted into ab-peptide and ex-
pressed at the cell surface, either because Iip10 was of IgG2 and IgG3 (Liu and Arpin, 1997).
Indeed, differences in protease use may be a ruledegraded by (an)other protease(s), or because Iip10
could be removed slowly without further degradation. among distinct APC: macrophages can overcome the
absence of Cat S because they express other enzymesIn addition, the ab-Iip10 complexes were transported
gradually to the plasma membrane, a surprising result absent from or low in B cells and DC, Cat L (Nakagawa
et al., 1999) or Cat F (Shi et al., 2000). Thymic epithelialbecause the cytoplasmic portion of Ii (and of Iip10) con-
tains signals for retention in intracellular compartments cells (TEC), responsible for positive selection of thymo-
cytes (Laufer et al., 1996), rely only on Cat L to cleave(Bakke and Dobberstein, 1990; Amigorena et al., 1995;
Brachet et al., 1997). The contribution of both ab-peptide Iip10 (Nakagawa et al., 1998). In TEC from Cat L±deficient
mice, the total amount of surface class II was normal,and ab-Iip10 resulted in a wild-type level of expression
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but one-half of the molecules was associated with Iip10 but the exact point of intersection varies among different
APC (Geuze, 1998). The majority of the class II moleculesand the other half with regular peptides. This resembled
the situation described for Cat S2/2 B cells and DC, acquire their peptide cargo relatively late in the so-called
MIIC or CIIV compartments (Figure 1). Other than thewhose antigen-presenting properties in the Cat L±defi-
cient animals were normal due to the expression of presence of the specialized machinery involved in acqui-
sition of peptide cargo, the basic attributes of theseCat S.
The role of Cat L in the TEC was demonstrated by compartments in APC do not differ from those in the
endocytic compartments of other cell types (Geuze,impaired positive selection of CD41 T cells in Cat L null
mice, whose thymi and lymph nodes contained one- 1998).
Lysosomes were long considered end-stations fromthird the normal amount of CD41 T cells (Nakagawa et
al., 1998). The decrease in the amount of peptide-bound which endocytosed material could not escape. Class II
molecules would have to acquire peptide and shuttle toclass II molecules on the surface of the Cat L2/2 TEC
would be responsible for the deficiency. Why can't Cat the cell surface before reaching the lysosomes. In fresh
DC extracted from the spleens of mice treated with flt3L2/2 TEC, which express at their surface half the normal
level of ab-peptide, drive the selection of more CD41 T ligand, a growth factor that provokes massive accumu-
lation of DC, the transient presence ab-Iip10 was notedcells? A single class II±peptide combination expressed
at modest levels can promote the selection of a relatively in all compartments of the endocytic route, including
lysosomes. Moreover, conversion of Iip10 into CLIPlarge and diverse set of CD41 T cells (Ignatowicz et
al., 1996); and H2-DM2/2 mice, which express class II could occur throughout the entire endocytic route and
was followed by the exchange of CLIP and the egress ofmolecules predominantly loaded with CLIP, possess a
similar or even larger number of CD41 T cells than the ab-peptide complexes to the cell surface. Consistently,
active Cat S was present in all endocytic compartments,Cat L knockout (Fung-Leung et al., 1996; Martin et al.,
1996; Miyazaki et al., 1996). An explanation for this para- as revealed by a radiolabeled protease probe selective
for this enzyme (Driessen et al., 1999). Thus, dendriticdox could be that the Iip10 complex has a dominant-
negative effect on positive selection of CD41 thymo- cells deficient in Cat S accumulated ab-Iip10 complexes
at all the stations of the endocytic route, including lyso-cytes. Alternatively, the absence of the elastinolytic and
collagenolytic activities of Cat L or of other enzyme(s) somes, where these complexes were long-lived. There-
fore, the abIi-p10 complex can survive even in lyso-whose activity might depend on Cat L may thwart the
remodeling of the extracellular matrix that is probably somes until Cat S catalyzes its conversion into ab-CLIP.
This might enable class II molecules to load antigenicnecessary for normal migration of the maturing thymo-
cytes towards the medullary areas of the thymus, just peptides, whose relative concentration at different com-
partments probably varies, along the entire endocyticas the lack of Cat K alone causes pycnodysostosis, a
disorder characterized by deficient bone formation route (Villadangos et al., 2000). It is in this scenario where
the widespread distribution of H2-DM in the endocytic(Gelb et al., 1996).
route also makes sense (Pierre et al., 1996), as does the
broad range of pH at which Cat S is active (Bromme etThe Influence of MHC Allelic Polymorphism
al., 1989).The affinity of the interaction of different MHC class II
allelic products with CLIP, and therefore with Ii, varies
(Malcherek et al., 1995; Sette et al., 1995). This polymor- A Regulatory Role for Cat S Activity?
phism is responsible for differences in abIi assembly Immature DC are specialized at capturing antigens and
and trafficking as well as in the requirement for H-2DM express low levels of MHC class II at their surface. These
to remove CLIP (Bikoff et al., 1995; Stebbins et al., 1995; cells mature when they receive signals associated with
Wolf et al., 1998). the presence of pathogens: mature DC no longer cap-
MHC polymorphism also influences the effect of Cat ture antigens and begin to express high levels of class
S inactivation: I-Ak, I-As, and I-Aq matured normally in the II at the plasma membrane (Banchereau and Steinman,
presence of Cat S inhibitors or in a Cat S2/2 background, 1998).
unlike I-Ab or I-Ad (Villadangos et al., 1997; Nakagawa et Modulation of the activity of Cat S has been proposed
al., 1999). In the absence of Cat S, ab-Iip10 accumulates. to control the change in MHC class II antigen-presenta-
Iip10 can probably be expelled from the binding site tion properties in mouse DC (Pierre and Mellman, 1998).
of some class II allelic products and substituted with In immature DC, the abIi trimers reach early endocytic
peptides, perhaps with the assistance of H-2DM (Denzin compartments and are converted into ab-Iip10, but the
et al., 1996; Sanderson et al., 1996; Stebbins et al., 1996; natural protease inhibitor Cystatin C (Abrahamson,
Kropshofer et al., 1997). 1994) blocks Cat S, so that instead of being converted
into ab-peptide, ab-Iip10 is transported to lysosomes
and degraded. In mature DC, Cystatin C is downregu-Compartmentalization of Proteolysis
in Antigen Presentation lated, the activity of Cat S increases, and Iip10 is
cleaved, allowing free ab dimers to capture peptidesAntigens taken up by the APC are gradually destroyed,
and the peptide content at different stations of the endo- and display them at the cell surface.
Analysis of DC from flt3-l-treated Cat S-deficient ani-cytic route is likely to vary (Watts, 1997). The location
where class II dimers become receptive to peptides may mals (whose phenotype is ªmatureº) suggests additional
mechanisms of control of class II trafficking. In thesedetermine the nature of material presented to T cells.
The point of entry of abIi into the endocytic route is cells the situation encountered by class II molecules in
endocytic compartments resembles that of immatureprobably at the junction of early and late endosomes,
Immunity
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Figure 2. Protease Specificity in the Genera-
tion of Antigenic Peptides
Left: class II molecules may capture antigenic
epitopes included in long polypeptide precur-
sors. Several proteases would subsequently
trim the unprotected regions. This mecha-
nism would not require any particular prote-
ase, as long as cleavage occurs.
Right: the generation of the epitopes shown
requires the participation of one or more dis-
tinct proteases. In the absence of A, no epi-
tope will be generated; the absence of either
B or C prevents the formation of ªcircleº with-
out affecting ªsquareº; ªtriangleº is not gener-
ated unless B is inactive and requires D. Inter-
mediate situations between the ªProtease
Dependentº (i.e., requiring a specific [set of]
protease[s]) and the ªProtease Independentº
(i.e., not requiring any particular protease)
scenarios might also exist.
DC, in that Cat S activity is absent, so that ab-Iip10 of Iip41 can provoke subtle alterations in the efficiency
of presentation of certain antigenic epitopes (Fineschicomplexes accumulate (see above). These complexes
not only survived for over 18 hr in lysosomes but were et al., 1996) and in the pattern of degradation of Ii
(Fineschi et al., 1995).transported slowly to the cell surface, where they were
long-lived (Driessen et al., 1999). The different fate of A distinct role for Iip41 was suggested when Cat L
was isolated from human kidney complexed with a frag-the ab-Iip10 complexes in immature DC (where they are
retained and degraded in lysosomes) and in Cat S2/2 ment of Iip41 that included its extra domain (Ogrinc et
al., 1993). This domain is structurally related to a novelDC (where they escape to the cell surface) implies that
other mechanisms of retention of class II molecules in- family of protease inhibitors named thyropins, which
includes the insulin-like growth factor binding proteindependent of signals encoded in Ii/Iip10 (i.e., encoded
in the a or b chains [Tan et al., 1997; Zhong et al., and the thyroglobulin domains (Lenarcic and Bevec,
1998). The Iip41 fragment inhibited Cat L but not Cat B1997]) must contribute to the retention of class II in
the endosomal compartments of immature DC. Indeed, or Cat S. Thus, the function of Iip41 could be to decrease
selectively the activity of Cat L in APC: Ii would stillretention of peptide-bound class II dimers in intracellular
compartments of immature DC has been described, de- be degraded by Cat S, while the half-life of potential
antigenic peptides that would otherwise be destroyedspite the absence of Ii in such ab-peptide complexes
(Pierre et al., 1997). by Cat LÐone of the most active proteasesÐwould
increase (Bevec et al., 1996).Regulation of class II trafficking, rather than proteo-
lytic activity, also appears to be the mechanism em- If the expression of Iip41 modulates Cat L activity, the
APC most sensitive to a change in Iip41 expressionployed by human DC to control antigen presentation. In
immature human DC, recycling of class II from the cell would probably be the TEC and perhaps macrophages
(see above) (Nakagawa et al., 1998, 1999). The normalsurface reduces the total amount at the plasma mem-
brane and ensures the maintenance of a large intracellu- maturation of CD41 thymocytes in mice that express
only Ii-p41 argues against a major effect of Ii-p41 onlar pool of molecules available to bind antigenic pep-
tides derived from endocytosed antigens. When human the activity of Cat L in TEC (Takaesu et al., 1995). Direct
association of Cat L with the Iip41 fragment has beenDC are stimulated, this recycling stops and peptide-
loaded class II accumulates at the cell surface (Cella et demonstrated thus far only in human kidney cells and
in assays in vitro, but an immunological role for thisal., 1997).
association remains to be established. In conclusion,
the experimental record does not at present support anIs Iip41 a Modulator of Cat L Activity?
immunological role for the association between Cat LIi exists in two forms that arise by alternative splicing,
and Iip41, although roles other than control of proteoly-the more abundant Iip31 (usually referred to simply as
sis remain a possibility.Ii) and Iip41 (Figure 1). Both Ii and Iip41 form complexes
with class II and are transported into the endocytic route,
where they are degraded. Mice expressing only one of Degradation of Antigens: Who and How?
The assessment of APC from mice deficient in Cat B,the Ii variants do not show major defects in class II
maturation, antigen presentation, or thymocyte devel- D, or L has shown that these enzymes may participate in
the generation of antigenic epitopes but that individuallyopment (Takaesu et al., 1995). However, the expression
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Table 2. Type II CystatinsTable 1. Lysosomal proteases
Cystatin ExpressionCysteine Proteases Expression
C ubiquitousCathepsin B ubiquitous
Cathepsin C ubiquitous D saliva, tears
E/M ubiquitousCathepsin F ubiquitous
Cathepsin H ubiquitous F/Leukocystatin hematopoietic cells
S saliva, tears, seminal plasmaCathepsin J placenta
Cathepsin K osteoclast SN saliva, tears, seminal plasma
SA saliva, tears, seminal plasmaCathepsin L ubiquitous
Cathepsin L2 thymus/testis/corneal epithelium
Cathepsin O ubiquitous
Cathepsin S antigen-presenting cells
Cathepsin W CD81 T cells/NK cells mechanism to overall peptide loading is unknown at
Cathepsin Z ubiquitous
present.Legumain/AEP ubiquitous
Other peptides may be first available for binding to
Aspartic Proteases Expression ab dimers in their approximate final size, and their gener-
ation could depend on the activity of one or more partic-Cathepsin D ubiquitous
Cathepsin E ubiquitous ular proteases (Figure 2, ªProtease Dependent,º i.e., re-
Napsin A lung/kidney quiring a specific [set of] protease[s]). An antigenic
Napsin B cells of the immune system polypeptide segment may require the initial ªunlockingº
of the protein that bears the epitope by a particular
protease (protease A in Figure 2) (Bogyo and Ploegh,
each one is dispensable: Cat D2/2 APC could present
1998), a process in which reduction of S-S bonds, if
to T cell hybridomas 15 different MHC class II 1 peptide
present, may play an essential role (Collins et al., 1991).
combinations as efficiently as their wild-type counter-
Presentation of the antigen tetanus toxin required a key
parts (Deussing et al., 1998). Similar results were ob-
cleavage by asparaginyl endopeptidase, a mammalian
tained for a smaller number of epitopes when the APC
homolog of legumain (Manoury et al., 1998). Conversely,
assessed were Cat B± or L±deficient splenocytes
the inactivation of one or more proteases may enhance
(Deussing et al., 1998; Nakagawa et al., 1998). The lack of
the survival of certain peptides (Figure 2).
Ii degradation hampers the interpretation of the assays
performed with Cat S2/2 APC: presentation of an OVA-
derived peptide was blocked but that of a HEL-derived Pharmacological Applications
Injection of mice with the inhibitor LHVS resulted in theepitope was enhanced (Nakagawa et al., 1999; Shi et
al., 1999). Perhaps the survival of this particular HEL- selective inhibition of Cat S in splenocytes. Like the Cat
S2/2 mice, LHVS-treated animals mounted poor re-derived peptide increases in the absence of Cat S, or it
is bound preferentially by class II molecules associated sponses against OVA but without other major side-
effects (Riese et al., 1998). In a different study, Cat S2/2with Iip10 or by peptide-bound ab dimers recycled from
the cell surface (Pinet et al., 1995). mice were more resistant to collageninduced arthritis,
but the effect of Cat S inhibitors in this or other modelsThe proteolytic activities involved in antigen pro-
cessing are probably more redundant than those in- of autoimmunity has not been tested yet (Nakagawa et
al., 1999).volved in break down of Ii. The timing and location at
which the peptide-receptive class II molecules become Treatment with protease inhibitors could either en-
hance or block the presentation of certain antigens inavailable are presumably under some level of control,
and this could be achieved if the proteases that degrade a selective manner, depending on several factors. The
first is obviously the intrinsic specificity of the inhibitorIi are discrete. On the other hand, to generate a wide
array of different peptides using a combination of sev- (Bogyo et al., 1998). Second is the role of the targeted
protease(s) in antigen processing. Third, in Cat S2/2 oreral proteasesÐsome with overlapping specificitiesÐ
may be the most efficient way of ensuring that CD41 T Cat L2/2 APC, the kinetics of maturation of class II are
drastically reduced, but presentation of many peptidescells will detect the presence of foreign epitopes.
Class II molecules may also play an active role in still occurs and for some it may even be enhanced (see
above). Pharmacological inhibition would be expectedselecting antigenic determinants present in long poly-
peptides, to be trimmed subsequently by endo- and to yield a similar diversity in effect. Fourth, each class
II allelic product is affected differently by the inhibitionexoproteases to remove the areas not buried in the
peptide binding site (Werdelin, 1986). The specificity of of Cat S (Villadangos et al., 1997) and hence the conse-
quences of protease inactivation might vary with MHCthe proteases would then be less relevant in determining
the peptides that will be eventually presented at the haplotype. Fifth, distinct APC may employ a different
set of proteases for antigen processing, just like TEC,cell surface (Figure 2, ªProtease Independent,º i.e., not
requiring a specific protease). The immunodominance DC, B cells, and macrophages differ in their use of Cat
L and/or Cat S for Ii degradation. Inactivation of oneof different regions of HEL is determined by the MHC
background and supports an active role of the class II enzyme could affect the antigen-presenting capabilities
of certain APC without affecting others. LHVS-treatedmolecules themselves in epitope selection (Moudgil et
al., 1997). Class II dimers can indeed associate with long mice were less responsive to OVA in a model of pulmo-
nary hypersensitivity than in mounting humoral re-polypeptides that are probably converted into smaller
peptides (Castellino et al., 1998; Deng et al., 1993; Nel- sponses against the same protein injected in CFA (Riese
et al., 1998).son et al., 1997), but the relative contribution of this
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